Hong Y. He

145 Studley Road
Heidelberg, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Thousand-And-One Kinase 3 in Pancreatic Ductal Adenocarcinoma Stemness, Microenvironment and Therapy Resistance.

Thousand-And-One Kinase 3 in Pancreatic Ductal Adenocarcinoma Stemness, Microenvironment and Therapy Resistance.

Journal: International journal of molecular sciences

Published: June 27, 2026

The interplay between p21-activated kinases and tumour-infiltrating dendritic cells and T cells and its implication in pancreatic cancer immunotherapy.

The interplay between p21-activated kinases and tumour-infiltrating dendritic cells and T cells and its implication in pancreatic cancer immunotherapy.

Journal: Cell communication and signaling : CCS

Published: March 02, 2026

Knockout of PAK1 and PAK4 supresses tumour growth associated with vasculogenic mimicry inhibition through EphA2-VE-cadherin-MCAM pathway.

Knockout of PAK1 and PAK4 supresses tumour growth associated with vasculogenic mimicry inhibition through EphA2-VE-cadherin-MCAM pathway.

Journal: Cell communication and signaling : CCS

Published: January 20, 2026

A Streamlined Protocol for Developing a Clinicopathological Prediction Model for Patient Survival of Post-Resection of Pancreatic Cancer.

A Streamlined Protocol for Developing a Clinicopathological Prediction Model for Patient Survival of Post-Resection of Pancreatic Cancer.

Journal: Cancer medicine

Published: October 26, 2025

Evaluation of Nanoparticle-Based Plasma Enrichment on Individuals with Primary and Metastatic Pancreatic Cancer.

Evaluation of Nanoparticle-Based Plasma Enrichment on Individuals with Primary and Metastatic Pancreatic Cancer.

Journal: Cancers

Published: September 29, 2025

Targeting PAK1 or PAK4 Uncovers Different Mechanisms of Vascular Reprogramming in Pancreatic Cancer.

Targeting PAK1 or PAK4 Uncovers Different Mechanisms of Vascular Reprogramming in Pancreatic Cancer.

Journal: Cells

Published: September 24, 2025

The Effects of PAK-Regulated Tumour Vasculature on Gemcitabine Response of Pancreatic Cancer.

The Effects of PAK-Regulated Tumour Vasculature on Gemcitabine Response of Pancreatic Cancer.

Journal: Cancers

Published: September 09, 2025

P-21 Kinase 1 or 4 Knockout Stimulated Anti-Tumour Immunity Against Pancreatic Cancer by Enhancing Vascular Normalisation.

P-21 Kinase 1 or 4 Knockout Stimulated Anti-Tumour Immunity Against Pancreatic Cancer by Enhancing Vascular Normalisation.

Journal: International journal of molecular sciences

Published: August 05, 2025

Knockout of p21-Activated Kinase 4 Stimulates MHC I Expression of Pancreatic Cancer Cells via an Autophagy-Independent Pathway.

Knockout of p21-Activated Kinase 4 Stimulates MHC I Expression of Pancreatic Cancer Cells via an Autophagy-Independent Pathway.

Journal: Cancers

Published: December 21, 2024

Core charge of imidazolium annulated triphenylene derivatives induces discotic columnar mesomorphism.

Core charge of imidazolium annulated triphenylene derivatives induces discotic columnar mesomorphism.

Journal: Soft matter

Published: September 24, 2024

A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine.

A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine.

Journal: International journal of molecular sciences

Published: September 13, 2024

Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?

Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?

Journal: Drug discoveries & therapeutics

Published: April 03, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026